# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Vaccinex (NASDAQ:VCNX) reported quarterly losses of $(0.33) per share. This is a 98.57 percent increase over losses of $(23.10)...
Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb® Drug Discovery Platform ActivMab® platfor...